{"id":"W4385064330","doi":"10.1002/pbc.30584","title":"Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms","year":2023,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Astellas Pharma; National Institutes of Health; Incyte; bluebird bio; Leukemia and Lymphoma Society; Jazz Pharmaceuticals; Syndax Pharmaceuticals; CureSearch for Children's Cancer; St. Baldrick's Foundation; Servier; Amgen","keywords":"Medicine; Gemtuzumab ozogamicin; Oncology; Internal medicine; Clinical trial; Sorafenib; Myeloid leukemia; Hematopoietic stem cell transplantation; CD33; Disease; Hematology; Intensive care medicine; Stem cell; CD34","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00254715,0.0003041535,0.0006282593,0.001143054,0.0003655914,0.00004966476,0.0005183025,0.0004042657,0.0005654148],"category_scores_gemma":[0.001100219,0.0002753127,0.0002590132,0.003280222,0.0002207111,0.0001080596,0.0005199267,0.001368741,0.001284562],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000718089,"about_ca_system_score_gemma":0.00228749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00139457,"about_ca_topic_score_gemma":0.0002965995,"domain_scores_codex":[0.9954224,0.0002107609,0.0005222052,0.0009616957,0.001129051,0.001753914],"domain_scores_gemma":[0.9966056,0.001312707,0.0001211539,0.000745127,0.0005906383,0.0006247188],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.00177037,0.001006067,0.2439606,0.001151604,0.0009516111,0.0005270185,0.0009669904,0.0001090976,0.004704111,0.0009703522,0.6832389,0.06064332],"study_design_scores_gemma":[0.03053385,0.006429843,0.5689656,0.0001687847,0.002386607,0.0004174398,0.000916681,0.001677532,0.004841617,0.002435384,0.3797632,0.001463435],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795056,0.002745649,0.00006111873,0.0107199,0.0008063841,0.002759406,0.0002478311,0.0004222455,0.002731866],"genre_scores_gemma":[0.9016391,0.03949101,0.003059965,0.001362435,0.0263603,0.006305559,0.0006036426,0.0003504804,0.02082752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3250051,"threshold_uncertainty_score":0.9999699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09014931244591472,"score_gpt":0.4150112182774019,"score_spread":0.3248619058314872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}